GitLife Biotech

GitLife Biotech

Biotechnology Research

GitLife Biotech enables proof of ownership in synthetic biology via the VCS www.CellRepo.com and DNA-based biosecurity.

About us

GitLife Biotech has launched www.CellRepo.com, the version control system for synthetic biology, alongside a suite of DNA-based biosecurity tools. Our technologies enable reproducibility and proof of ownership, facilitating scale in synthetic biology. To tie the VCS to the engineered asset we must mark the genome of the biological asset itself. To do so we have developed DNA barcodes to an unprecedented level of sophistication: creating biosecurity tools with varying levels of confidentiality and indelibility. Our protocols cover 90% of the strains used in engineering biology and we are developing more all the time. See www.CellRepo.com for more information and to register. We are a Newcastle University spin out, co-founded with the venture builder Cambridge Future Tech Ltd. We maintain laboratories and offices in both Newcastle and Cambridge, UK.

Website
www.gitlifebiotech.com
Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Newcastle
Type
Privately Held
Founded
2023

Locations

Employees at GitLife Biotech

Updates

Similar pages

Funding

GitLife Biotech 1 total round

Last Round

Pre seed
See more info on crunchbase